Ongoing trials are evaluating frontline treatment using BV-CHP in PTCL with less than 10% CD30 expression (NCT04569032), as well as a similar BV-CHEP regimen which includes the addition of etoposide (NCT05006664). This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.